Effects of Coxsackievirus B3 infection on the expression of diabetes-related LncRNA in islet cells

doi:10.12092/j.issn.1009-2501.2019.10.004

Abstract

Abstract:

AIM: To explore the specific mechanism of diabetes mellitus induced by Coxsackievirus B3. METHODS: Human islet cells HUM-CELL-0058 were infected with Coxsackievirus B3. Total RNA was extracted 48 hours after infection and LncRNA related to diabetes mellitus was detected by fluorescence quantitative PCR. Real-time quantitative PCR and Western blot were used to monitor the transcription factors and proteins regulating the transcription of three LncRNA. The over-expression plasmids of PAX6 and NF-kappa B were constructed and transfected into B cells infected with the virus to detect the abnormal expression of LncRNA after coxsackievirus infection. RESULTS:Diabetes-related LncRNA, Lnc-P12792 and MALT1 were up-regulated, while HI-Lnc45 was down-regulated. Real-time quantitative PCR and Western blot results showed that the expression of PAX6, a transcription factor regulating HI-Lnc45 expression, decreased while the expression of NF-kappa B, a transcription factor regulating Lnc-P12792 and MALT1, increased, which was consistent with the trend of transcription factors regulated by PAX6, indicating that the expression difference of LncRNA was due to the abnormal expression of transcription factors of the gene. Real-time quantitative results showed that the three abnormal expression levels of LncRNA returned to the normal level before coxsackievirus B3 infection, which proved that this trend could be saved by regulating the expression of these two transcription factors. CONCLUSION: Coxsackievirus B3 infection of human pancreatic islet β cells can induce up-regulation of transcription factor NF-kappa B and down-regulation of PAX6, and induce abnormal expression of LncRNA related to diabetes mellitus downstream, which may be one of the pathological mechanisms of Coxsackievirus B3 induced diabetes mellitus.

Key words: type B3 Coxsackie virus, diabetes, LncRNA, transcription factor

CLC Number:

R587
R373.1

SHEN Yajing, LI Lanjuan. Effects of Coxsackievirus B3 infection on the expression of diabetes-related LncRNA in islet cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1101-1106.

References

［1］Woodruff JF. Viral myocarditis. A review［J］. Am J Pathol, 1980,101(2):425-484.
［2］Wessely R, Henke A, Zell R, et al. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes［J］. Circulation, 1998,98(5):450-457.
［3］Colli ML, Paula FM, Marselli L, et al. Coxsackievirus B tailors the unfolded protein response to favour viral amplification in pancreatic beta cells［J］. J Innate Immun, 2019,11(4):375-390.
［4］Whitton JL, Cornell CT, Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism［J］. Nat Rev Microbiol, 2005, 3(10):765-776.
［5］Engelmann I, Alidjinou EK, Bertin A, et al. Persistent coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic cells［J］. Cell Mol Life Sci, 2017,74(20):3851-3861.
［6］Kolehmainen P, Koskiniemi M, Oikarinen S, et al. Human parechovirus and the risk of type 1 diabetes［J］. J Med Virol, 2013, 85(9):1619-1623.
［7］Badia-Boungou F, Sane F, Alidjinou EK, et al. Marker of coxsackievirus-B4 infection in saliva of patients with type 1 diabetes［J］. Diabetes Metab Res Rev, 2017,33(7).
［8］Stone VM, Hankaniemi MM, Svedin E, et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes［J］. Diabetologia, 2018, 61(2):476-481.
［9］Esfandiarei M, Boroomand S, Suarez A, et al. Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability［J］. Cell Microbiol, 2007, 9(10):2358-2371.
［10］Liu JY, Yao J, Li XM, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus［J］. Cell Death Dis, 2014, 5:e1506.
［11］Morán I, Akerman I, van de Bunt M, et al. Human beta cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes［J］. Cell Metab, 2012,16(4):435-448.
［12］Kornfeld JW, Brüning JC. Regulation of metabolism by long, non-coding RNAs［J］. Front Genet, 2014, 5:57.
［13］Ellis BC, Graham LD, Molloy PL. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism［J］. Biochim Biophys Acta, 2014, 1843(2):372-386.
［14］Shi Y, Tu H, Chen X, et al. The long non-coding RNA expression profile of Coxsackievirus A16 infected RD cells identified by RNA-seq［J］. Virol Sin, 2016, 31(2):131-141.
［15］Uesaka M, Nishimura O, Go Y, et al. Bidirectional promoters are the major source of gene activation-associated non-coding RNAs in mammals［J］. BMC Genomics, 2014,17;15:35.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[5]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[6]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[7]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[8]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[9]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[10]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[11]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[12]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[13]	LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu. FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
[14]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[15]	CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.